CV Outcomes with PCSK9 Inhibitors: selecting the right patient

Details & Video

Program Time: 30 minutes - includes presentation and interactivity
Accreditation-CME Credits: This online 1-credit-per-hour Self-Learning program has been certified by the College of Family Physicians of Canada for up to 0.5 Mainpro+ credits.
Target Audience: General Practitioners
Program available until: August 6, 2020
Program Preview
Click image above to play the program preview.

Overview & Objectives

CV Outcomes With PCSK9 Inhibitors

Target Audience: General Practitioners.

By participating in this educational program, health care providers will be able to:
  1. EXPLAIN the results of the PCSK9 inhibitor outcomes trials
  2. DEFINE the appropriate patient for PCSK9 inhibitors


This online 1-credit-per-hour Self-Learning program has been certified by the College of Family Physicians of Canada for up to 0.5 Mainpro+ credits.

This program was supported in part by educational funding from Amgen Canada

Claiming your credits: Please submit your credits for this activity online at Please retain proof of your participant for six (6) years in case you are selected to participate in credit validation or auditing.

Planning Committee & Faculty

Planning Committee & Faculty

Milan Gupta
Milan Gupta
Brampton, ON

Associate Clinical Professor of Medicine,
McMaster University

Medical Director
Canadian Collaborative Research Network

View disclosures

Jeffrey Habert
Jeffrey Habert
Toronto, Ontario

Assistant Professor,
University of Toronto,
Dept. of Family and Community Medicine

View disclosures

Daniel Ngui
Daniel Ngui
B. Sc., PT, M.D., FCMF
Vancouver, BC

Clinical Associate Professor
University of British Columbia

Medical Director
Fraser Street Medical

View disclosures

Marla Shapiro
Marla Shapiro
Toronto, Ontario

Professor, University of Toronto
Department of Family and Community Medicine

University Health Network
North York General, Mount Sinai

View disclosures



Program ChapterDuration
Landscape of PCSK9 Inhibitors3:40
PCSK9 Inhibitor Trials: Fourier3:54
PCSK9 Inhibitor Trials: SPIRE 1 and 22:41
PCSK9 Inhibitor Trials: ODYSSEY4:59
PCSK9 Inhibitor Guidelines4:28
Which Patients Deserve a PCSK9 Inhibitor?0:46



This program has been developed by the Canadian Collaborative Research Network, a not-for-profit physician organization, and is supported through an educational grant received from:

Amgen Canada

Links & Resources

Links & Resources:

  • Kotseva, K. et al European Journal of Preventive Cardiology, February 16, 2015.
  • deGoma, et al. “Circulation. Cardiovascular Genetics 9, no. 3 (June 2016): 240–49.
  • Pijlman, A. H., et al. Atherosclerosis 209, no. 1 (March 2010): 189–94.
  • Anderson, T, et al. Canadian Journal of Cardiology 32, no. 11 (November 2016): 1263–82.
  • Sabatine, M., et al. New England Journal of Medicine 372, no. 16 (April 16, 2015): 1500–1509.
  • Nicholls, S., et al. JAMA 316, no. 22 (December 13, 2016): 2373–84.
  • Sabatine MS, et al. N Engl J Med. 2017 May 4;376(18):1713-1722.
  • Ridker PM, et al. N Engl J Med. 2017 Apr 20;376(16):1527-1539.
  • Steg G, et al. Am College Cardiol. 2018 Mar 10; (suppl.)
  • Sabatine MS et al. N Engl J Med. 2017; epub ahead of print
  • Steg G et al. American College of Cardiology Scientific Sessions, 2018 – Orlando, FL
  • Schwartz GG, et al. Am Heart J 2014;168:682-689.e1.
  • Anderson TJ, et al. CJC, 2016: Jul.24(32):1263-1282.
  • Lloyd-Jones DM, et al. JACC, 2017: Oct.70(14).
  • CCS Dyslipidemia Guidelines:
  • (
  • (
  • European Atherosclerosis Society: